Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals (MIRM)
:MIRM
Total Valuation
Mirum Pharmaceuticals has a market cap or net worth of $1.94B. The enterprise value is $2.03B.
Market Cap$1.94B
Enterprise Value$2.03B
Share Statistics
Mirum Pharmaceuticals has 49.01M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49.01M
Owned by Insiders9.43%
Owned by Instutions40.60%
Financial Efficiency
Mirum Pharmaceuticals’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -16.24%.
Return on Equity (ROE)-38.97%
Return on Assets (ROA)-13.11%
Return on Invested Capital (ROIC)-16.24%
Return on Capital Employed (ROCE)-16.10%
Revenue Per Employee$1,046,236.025
Profits Per Employee-$273,111.801
Employee Count322
Asset Turnover0.50
Inventory Turnover3.64
Valuation Ratios
The current PE Ratio of Mirum Pharmaceuticals is -22.34. Mirum Pharmaceuticals’s PEG ratio is 0.42.
PE Ratio-22.34
PS Ratio5.83
PB Ratio8.71
Price to Fair Value8.71
Price to FCF210.57
Price to Operating Cash Flow190.32
PEG Ratio0.42
Income Statement
In the last 12 months, Mirum Pharmaceuticals had revenue of $336.89M and earned -$87.94M in profits. Earnings per share was -$1.85.
Revenue$336.89M
Gross Profit$255.25M
Operating Income-$87.61M
Pretax Income-$86.91M
Net Income-$87.94M
EBITDA-48.97M
Earnings Per Share (EPS)-1.85
Cash Flow
In the last 12 months, operating cash flow was $10.32M and capital expenditures -$10.99M, giving a free cash flow of $9.33M billion.
Operating Cash Flow$10.32M
Free Cash Flow$9.33M
Free Cash Flow per Share$0.19
Dividends & Yields
Mirum Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield0.47%
Earnings Yield-4.48%
Stock Price Statistics
Beta0.63
52-Week Price Change65.58%
50-Day Moving Average46.58
200-Day Moving Average42.65
Relative Strength Index (RSI)34.51
Average Volume (3m)512.58K
Important Dates
Mirum Pharmaceuticals upcoming earnings date is May 1, 2025, After Close.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Mirum Pharmaceuticals as a current ratio of 3.10, with Debt / Equity ratio of 1.41
Current Ratio3.10
Quick Ratio2.93
Debt to Market Cap0.16
Net Debt to EBITDA-1.95
Interest Coverage Ratio-6.12
Taxes
In the past 12 months, Mirum Pharmaceuticals has paid $1.03M in taxes.
Income Tax$1.03M
Effective Tax Rate-1.19%
Enterprise Valuation
Mirum Pharmaceuticals EV to EBITDA ratio is -42.07, with an EV/FCF ratio of 220.78.
EV to Sales6.12
EV to EBITDA-42.07
EV to Free Cash Flow220.78
EV to Operating Cash Flow199.55
Balance Sheet
Mirum Pharmaceuticals has $280.31M in cash and marketable securities with $317.76M in debt, giving a net cash position of $37.45M billion.
Cash & Marketable Securities$280.31M
Total Debt$317.76M
Net Cash$37.45M
Net Cash Per Share$0.76
Tangible Book Value Per Share-$0.51
Margins
Gross margin is 75.77%, with operating margin of -26.00%, and net profit margin of -26.10%.
Gross Margin75.77%
Operating Margin-26.00%
Pretax Margin-25.80%
Net Profit Margin-26.10%
EBITDA Margin-14.54%
EBIT Margin-21.55%
Analyst Forecast
The average price target for Mirum Pharmaceuticals is $63.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$63.75
Price Target Upside61.07%
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast80.76%
EPS Growth Forecast53.98%